8-K/ALeadership Changes

JOHNSON & JOHNSON 8-K/A Report, Executive Changes (Feb 15, 2023)

Filed February 15, 2023For Securities:JNJ

Summary

Johnson & Johnson (JNJ) has announced the appointment of Dr. Paula A. Johnson, President of Wellesley College, to its Board of Directors. This appointment is effective immediately and signifies a strategic addition to the company's leadership. Dr. Johnson brings a wealth of experience from her role at a prominent educational institution, which may offer a fresh perspective on governance and strategic direction. Furthermore, Dr. Johnson will be joining the Board's Nominating & Corporate Governance Committee starting April 27, 2023. This committee plays a crucial role in identifying and recommending director candidates and overseeing corporate governance policies. Her involvement in this committee suggests an emphasis on strengthening the company's governance framework and ensuring a robust pipeline of qualified board members. Investors should note that as a non-employee director, her compensation will align with the company's standard director compensation practices, as detailed in the upcoming 2023 Proxy Statement.

Key Highlights

  • 1Appointment of Dr. Paula A. Johnson to Johnson & Johnson's Board of Directors, effective immediately.
  • 2Dr. Johnson's appointment brings diverse leadership experience from her role as President of Wellesley College.
  • 3Dr. Johnson will serve on the Nominating & Corporate Governance Committee from April 27, 2023.
  • 4This move suggests a focus on enhancing corporate governance and board composition.
  • 5Compensation for Dr. Johnson as a non-employee director will follow established company policy outlined in the 2023 Proxy Statement.
  • 6The announcement was made via a press release filed as an exhibit to the 8-K/A.

Frequently Asked Questions

Dr. Paula A. Johnson is the President of Wellesley College. Her academic leadership experience is expected to bring valuable insights to Johnson & Johnson's Board of Directors.

Dr. Johnson will be joining the Nominating & Corporate Governance Committee, effective April 27, 2023. This committee is responsible for board nominations and overseeing corporate governance.

As a non-employee director, Dr. Johnson will receive compensation as described in the 'Director Compensation' section of Johnson & Johnson's 2023 Proxy Statement.

While the addition of a new director is standard practice, Dr. Johnson's appointment to the Nominating & Corporate Governance Committee indicates a continued focus on strong governance and board effectiveness. Investors will want to monitor how her contributions align with the company's strategic objectives.